- Active not recruitingPHASE3
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
This study looks at how well a medicine called risankizumab works and how safe it is for people with ulcerative colitis. It's for those who have already shown improvement with this medicine in a previous study.
For: Ulcerative Colitis (UC)United States · Argentina · Austria - RecruitingPHASE3
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new treatment called risankizumab for children and young people aged 2 to 17 with Crohn's disease that hasn't responded well to other medicines. Scientists want to see if it's safe, helps their symptoms, and how it works in their bodies.
For: Crohn's DiseaseUnited States · Belgium · Bulgaria - RecruitingPHASE3
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
This study is looking at a medicine called risankizumab for children and young people with ulcerative colitis (UC). It aims to see how well and safely it works, and how it moves through the body, for those aged 2 to 17 with moderate to severe UC.
For: Ulcerative ColitisUnited States · Belgium · Brazil - Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
For: Crohn's Disease (CD)United States · Argentina · Australia - RecruitingPHASE2
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
This study looks at new medications for adults with moderate to severe Crohn's disease. Researchers want to see how well these 'targeted therapies' work and if they cause side effects, to find better ways to manage the condition.
For: Crohn's DiseaseUnited States · Austria · Belgium - RecruitingPHASE3
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
This study compares two medicines, guselkumab and risankizumab, for people with moderate to severe Crohn's disease. Researchers want to see which one works better to reduce inflammation in the gut and improve symptoms.
For: Crohn DiseaseUnited States · Austria · Belgium - RecruitingPHASE3
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
This study looks at a new medicine called risankizumab for children aged 5-17 with a type of arthritis called juvenile psoriatic arthritis (jPsA). It aims to see how safe and effective it is compared to an existing medicine, adalimumab. Participants will receive injections.
For: Juvenile Psoriatic ArthritisUnited States · Australia · Canada - Active not recruitingPHASE3
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
This study is testing a new medicine called sonelokimab for adults with psoriatic arthritis that hasn't responded well to previous treatments. We want to see if it's safe and helps improve their symptoms compared to a dummy treatment or an existing medicine.
For: Arthritis, PsoriaticUnited States · Bulgaria · Canada - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
This study is testing a new medicine called bimekizumab for adults with active psoriatic arthritis. It compares bimekizumab to another medicine, risankizumab, and a dummy treatment (placebo), to see how well it works and if it's safe over 16 weeks.
For: Psoriatic ArthritisUnited States · Australia · Bulgaria - Active not recruitingPHASE3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
This study is testing a new medicine, risankizumab, for adults with active psoriatic arthritis, especially those who haven't responded well to other treatments. It aims to see how safe and effective it is in reducing symptoms.
For: Psoriatic Arthritis (PsA)United States · Argentina · Australia - Active not recruitingPHASE3
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
This study looks at a medicine called risankizumab for children aged 6 to 17 with moderate to severe psoriasis. It checks for side effects and how well the medicine works in those who were part of an earlier study. Risankizumab is already used for adults with psoriasis.
For: PsoriasisUnited States · Canada · Germany - Active not recruitingPHASE3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
This study compares two approved medicines, risankizumab and vedolizumab, for adults with moderate to severe ulcerative colitis who haven't tried similar treatments before. It looks at how safe and effective they are. Around 530 people will take part worldwide.
For: Ulcerative ColitisUnited States · Austria · Bulgaria - Active not recruitingPHASE3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
This study compares a new medicine, risankizumab, with a dummy treatment (placebo) for people with active psoriatic arthritis. It checks how safe and effective risankizumab is, especially for those who haven't responded well to other treatments.
For: Psoriatic ArthritisUnited States · Argentina · Australia